The STOP-HCV-1 clinical trial will assess two direct acting anti-viral (DAA) treatment combinations and whether the addition of another, older drug has value in short course treatment
Medical test
There are no molecular diagnostic tests to predict patients' response to DAA treatment.
Genedrive PLC (LON:GDR), the molecular diagnostics company, said its Genedrive point-of-care IL28B human genotyping test is to be used in a Hepatitis C clinical trial.
The STOP-HCV-1 clinical trial is being run by STOP-HCV, a consortium designed to use stratified medicine to optimise the treatment of patients with Hepatitis C Virus infection, and it will use the Genedrive test to quickly process cheek swab tests, saving weeks on the normal process, which involves sending swabs off to a lab for processing.
"We are pleased to incorporate the Genedrive IL28B point of care genotyping test in the STOP-HCV-1 clinical trial, which aims to identify key markers to guide the duration of treatment required for HCV patients," said Dr Graham Cooke, chief investigator of the STOP-HCV-1 clinical trial.
David Budd, the chief executive of Genedrive, said inclusion of the company’s IL28B test in the study provided further validation of the potential of the Genedrive device in point-of-care genotype – the genetic make-up of an organism or group of organisms - diagnostic testing.
“If the STOP-HCV-1 clinical trial demonstrates that the IL28B genotype is a reliable indication of patient response to shortened DAA treatment, we would anticipate a role for the Genedrive IL28B test in future HCV treatments. The Genedrive IL28B test has been developed alongside the Genedrive HCV test which is scheduled for market launch in 2017," Budd revealed.
Genedrive was formerly known as EpiStem Holdings PLC.
The shares were of 2.5p at 80p in the first hour of trading.
Medical test
There are no molecular diagnostic tests to predict patients' response to DAA treatment.
Genedrive PLC (LON:GDR), the molecular diagnostics company, said its Genedrive point-of-care IL28B human genotyping test is to be used in a Hepatitis C clinical trial.
The STOP-HCV-1 clinical trial is being run by STOP-HCV, a consortium designed to use stratified medicine to optimise the treatment of patients with Hepatitis C Virus infection, and it will use the Genedrive test to quickly process cheek swab tests, saving weeks on the normal process, which involves sending swabs off to a lab for processing.
"We are pleased to incorporate the Genedrive IL28B point of care genotyping test in the STOP-HCV-1 clinical trial, which aims to identify key markers to guide the duration of treatment required for HCV patients," said Dr Graham Cooke, chief investigator of the STOP-HCV-1 clinical trial.
David Budd, the chief executive of Genedrive, said inclusion of the company’s IL28B test in the study provided further validation of the potential of the Genedrive device in point-of-care genotype – the genetic make-up of an organism or group of organisms - diagnostic testing.
“If the STOP-HCV-1 clinical trial demonstrates that the IL28B genotype is a reliable indication of patient response to shortened DAA treatment, we would anticipate a role for the Genedrive IL28B test in future HCV treatments. The Genedrive IL28B test has been developed alongside the Genedrive HCV test which is scheduled for market launch in 2017," Budd revealed.
Genedrive was formerly known as EpiStem Holdings PLC.
The shares were of 2.5p at 80p in the first hour of trading.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.